Celltrion
FDA Approves Herzuma for Breast Cancer
The FDA approved Herzuma, a HER2/neu receptor antagonist biosimilar to Herceptin for breast cancer treatment.
DECEMBER 17, 2018
FDA Approves Truxima, First Biosimilar to Rituxan
The FDA approved rituximab-abbs (Truxima, Celltrion/Teva), the first biosimilar to rituximab (Rituxan, ...
DECEMBER 1, 2018
Load more